DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 hour ago

PFE·Pfizer Inc.

$.
-. (-.%)
High
$25.96
Open
$25.87
Market Cap
147.62B
52W High
$28.75
Low
$25.67
P. Close
$25.90
P/E
19.71
52W Low
$22.81
Fwd P/E
9.13
Mean Target
-
Technical Score (1D)
27
SELL
News Sentiment
57
BULLISH
Pfizer's (PFE) investment narrative is currently shaped by a divergence of analyst opinions, with some optimistic about pipeline advancements in areas like oncology and GLP-1 programs, while others express significant concern over upcoming patent cliffs. This split is reflected in divided price targets, indicating uncertainty about future growth drivers and long-term earnings visibility. A recent development shows the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending a combination therapy involving a PFE drug for muscle-invasive bladder cancer, a decision that could establish a new standard of care if approved by the European Commission in Q3 2026. This positive regulatory news comes as the branded pharmaceuticals sector, including Pfizer, concluded its Q1 earnings season with mixed results, though revenues marginally beat consensus. The industry faces tailwinds from precision medicine and AI in drug development, but also headwinds from regulatory scrutiny, pricing pressures, and significant revenue risks from patent expirations. Specifically, major drug patent expirations for Pfizer are scheduled for 2028, with potential losses estimated between $15 billion and $20 billion, raising concerns about dividend sustainability as the payout ratio has exceeded 100%. Investors are therefore weighing near-term regulatory wins against these substantial long-term revenue challenges. Looking ahead, market participants will be watching the European Commission's final decision on the bladder cancer therapy and continued developments in Pfizer's pipeline to gauge future performance.
Earnings Summary
Pfizer is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and distributing innovative medicines and vaccines across various therapeutic areas, including oncology and infectious diseases. Operating within the broader Healthcare sector, specifically the Drug Manufacturers - General industry, Pfizer leverages strategic collaborations and a long history to address unmet medical needs worldwide. In its most recent reported quarters, Pfizer demonstrated a trend of exceeding earnings per share (EPS) estimates, with actual EPS of $0.75 in Q1 2026 surpassing the estimate of $0.72, and $0.66 in Q4 2025 exceeding the estimate of $0.58. This follows a pattern of strong EPS beats in prior periods, such as Q3 2025 ($0.87 actual vs. $0.63 estimate) and Q2 2025 ($0.78 actual vs. $0.57 estimate). Revenue figures, where available, show a mixed trend, with Q1 2026 revenue of $14.45 billion beating the estimate of $13.80 billion, while Q4 2025 revenue of $17.56 billion also exceeded its estimate of $17.12 billion. Historically, Pfizer has shown a capacity to deliver strong EPS performance against analyst expectations, notably beating estimates in at least the last four reported quarters for which data is available. The company's revenue growth trajectory has been variable, but recent quarters indicate a return to revenue beats. Recent news highlights Pfizer's strategic expansion in oncology through an alliance with Sarah Cannon Research Institute and licensing of a breast cancer therapy, alongside the CEO's reported leverage of artificial intelligence for business decisions. However, these developments occur amidst analyst caution, with a "Hold" rating and a consensus price target of $28.61, reflecting concerns about stock underperformance, absence in the GLP-1 market, and looming patent expirations. Investors will be watching for the impact of these strategic oncology initiatives and the integration of AI on future performance, alongside any shifts in analyst sentiment or institutional investor positioning in the upcoming quarters.

EPS

EstBeatMiss
$0.52$0.63$0.75$0.86$0.97Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$0.68 - -
Q1'26$0.72$0.75+3.9%
Q4'25$0.58$0.66+14.3%
Q3'25$0.63$0.87+37.4%
Q2'25$0.57$0.78+35.9%
Q1'25$0.67$0.92+36.5%

Revenue

EstBeatMiss
$13.1B$14.4B$15.6B$16.9B$18.1BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$14.6B - -
Q1'26$13.8B$14.5B+4.7%
Q4'25$17.1B$17.6B+2.6%
Q3'25 - $16.7B -
Q2'25 - $14.7B -
Q1'25 - $13.7B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

PFE Stock Snapshot

PFE is currently trading at $25.78, giving Pfizer Inc. a market cap of 147.62B and a P/E ratio of 19.7. Today's range spans $25.67–$25.96, with shares opening at $25.87 and moving down $0.12 (0.5%) from the prior close. DailyIQ's technical score sits at 27/100 (SELL) with a news sentiment reading of 57/100.

Over the past year PFE has traded between $22.81 and $28.75 - the current price is +13.0% off the 52-week low and -10.3% from the high.

The bearish momentum on Pfizer Inc. (PFE) - 27/100 (SELL), sentiment neutral at 57/100, price $25.78 (in the middle of its 52-week range) - is the type of setup where stop-loss selling from long-side momentum strategies amplifies the initial technical weakness. The current P/E ratio stands at 19.7. At 147.62B in Healthcare market cap, the 52-week range of $22.81–$28.75 provides the structural reference, and the lower end of that range becomes the next key test if the current SELL signal persists.

Analyst coverage for PFE becomes a double-edged factor in a SELL phase: at 147.62B in Healthcare market cap, active coverage is high enough that downgrade risk is real and impactful. The 27/100 technical reading and neutral sentiment (57/100) at $25.78 (in the middle of its 52-week range) place the stock in the zone where one or two high-profile estimate cuts can convert a grinding decline into a sharper re-rating — the $22.81–$28.75 range establishes where that repricing lands.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…